Table 3.
The association between use of different antiplatelet agents and bleeding outcomes using an extended cox model.
| Outcome | Events (n) | Nonadjusted model | Model I | Model 2 | ||||
|---|---|---|---|---|---|---|---|---|
| Ticagrelor (n = 108) | Clopidogrel (n = 168) | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Total BARC bleedings | 39 (36.1) | 37 (22.0) | 1.88 (1.12∼3.15) | 0.026 | 1.96 (1.17∼3.28) | 0.021 | 3.01 (1.81∼5.62) | 0.010 |
| BARC 1 or 2 bleedings | 25 (23.1) | 24 (14.3) | 1.83 (0.97∼3.46) | 0.064 | 2.06 (1.08∼3.92) | 0.038 | 3.14 (1.52∼5.76) | 0.018 |
| BARC 3 or 5 bleedings | 14 (13.0) | 13 (7.7) | 1.98 (0.83∼4.77) | 0.116 | 1.9 (0.79∼4.56) | 0.101 | 2.87 (1.12∼7.03) | 0.045 |
Notes. data presented are HRs and 95% CIs. Adjust I model adjusts for age and gender; adjust II model adjust for variables that, when added to this model, changed the matched odds ratio by at least 10 percent, including adjusting for adjust I + smoking status, diabetes, diagnosis, congestive heart failure, COPD, stroke history, heart rate, hemoglobin, ejection fraction, hs-cTn T, Nt-proBNP, eGFR, dialysis, GP IIb/IIIa inhibitors, 3-vessel disease.